Literature DB >> 18311684

Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report.

M N Hill1, G E Miller, W-S V Ho, B B Gorzalka, C J Hillard.   

Abstract

BACKGROUND: Preclinical research has suggested that the endocannabinoid system may be involved in the etiology and/or treatment of depression; however, there are no published studies examining circulating endocannabinoid content in patients with clinical depression.
METHODS: This study examined the endocannabinoids (anandamide; AEA) and 2-arachidonylglycerol (2-AG) in serum from ambulatory, medication-free female patients diagnosed with minor or major depression, and in controls matched for demographic characteristics.
RESULTS: Serum 2-AG content was significantly decreased in patients diagnosed with major depression, and this decrease was correlated significantly and negatively with duration of the depressive episode, such that 2-AG content was progressively lower the longer the depressive episode. While AEA was not associated with major depression PER SE, a strong negative correlation was found between serum AEA content and Hamilton ratings for cognitive and somatic anxiety, suggesting that AEA content may relate to the anxiety dimension of affective disorders. In subjects with minor depression, serum AEA was significantly elevated, with 2-AG content demonstrating a similar, but statistically insignificant trend. DISCUSSION: These are the first clinical data to indicate that the endocannabinoid system may be disturbed in affective disease, and suggest that future research is required to determine the relevance of these changes with respect to disease manifestation and pharmacotherapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18311684      PMCID: PMC3422568          DOI: 10.1055/s-2007-993211

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  38 in total

Review 1.  Endocannabinoids as cardiovascular modulators.

Authors:  G Kunos; Z Járai; S Bátkai; S K Goparaju; E J Ishac; J Liu; L Wang; J A Wagner
Journal:  Chem Phys Lipids       Date:  2000-11       Impact factor: 3.329

Review 2.  Depresssion--emerging insights from neurobiology.

Authors:  V A Vaidya; R S Duman
Journal:  Br Med Bull       Date:  2001       Impact factor: 4.291

Review 3.  The corticosteroid receptor hypothesis of depression.

Authors:  F Holsboer
Journal:  Neuropsychopharmacology       Date:  2000-11       Impact factor: 7.853

4.  The Depression Interview and Structured Hamilton (DISH): rationale, development, characteristics, and clinical validity.

Authors:  Kenneth E Freedland; Judith A Skala; Robert M Carney; James M Raczynski; C Barr Taylor; Carlos F Mendes de Leon; Gail Ironson; Marston E Youngblood; K Ranga Rama Krishnan; Richard C Veith
Journal:  Psychosom Med       Date:  2002 Nov-Dec       Impact factor: 4.312

5.  Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress.

Authors:  Matthew N Hill; Sachin Patel; Erica J Carrier; David J Rademacher; Brandi K Ormerod; Cecilia J Hillard; Boris B Gorzalka
Journal:  Neuropsychopharmacology       Date:  2005-03       Impact factor: 7.853

6.  Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test.

Authors:  Matthew N Hill; Boris B Gorzalka
Journal:  Eur Neuropsychopharmacol       Date:  2005-12       Impact factor: 4.600

7.  Involvement of CB1 cannabinoid receptors in emotional behaviour.

Authors:  Miquel Martin; Catherine Ledent; Marc Parmentier; Rafael Maldonado; Olga Valverde
Journal:  Psychopharmacology (Berl)       Date:  2001-11-20       Impact factor: 4.530

Review 8.  Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression?

Authors:  M N Hill; B B Gorzalka
Journal:  Behav Pharmacol       Date:  2005-09       Impact factor: 2.293

9.  Estrogen recruits the endocannabinoid system to modulate emotionality.

Authors:  Matthew N Hill; Eda S Karacabeyli; Boris B Gorzalka
Journal:  Psychoneuroendocrinology       Date:  2007-03-27       Impact factor: 4.905

10.  The endogenous cannabinoid system controls extinction of aversive memories.

Authors:  Giovanni Marsicano; Carsten T Wotjak; Shahnaz C Azad; Tiziana Bisogno; Gerhard Rammes; Maria Grazia Cascio; Heike Hermann; Jianrong Tang; Clementine Hofmann; Walter Zieglgänsberger; Vincenzo Di Marzo; Beat Lutz
Journal:  Nature       Date:  2002-08-01       Impact factor: 49.962

View more
  102 in total

1.  Circadian rhythm of circulating levels of the endocannabinoid 2-arachidonoylglycerol.

Authors:  E C Hanlon; E Tasali; R Leproult; K L Stuhr; E Doncheck; H de Wit; C J Hillard; E Van Cauter
Journal:  J Clin Endocrinol Metab       Date:  2015-01       Impact factor: 5.958

Review 2.  Sex differences in cannabinoid pharmacology: a reflection of differences in the endocannabinoid system?

Authors:  Rebecca M Craft; Julie A Marusich; Jenny L Wiley
Journal:  Life Sci       Date:  2012-06-20       Impact factor: 5.037

3.  Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructure.

Authors:  M N Hill; S A Kumar; S B Filipski; M Iverson; K L Stuhr; J M Keith; B F Cravatt; C J Hillard; S Chattarji; B S McEwen
Journal:  Mol Psychiatry       Date:  2012-07-10       Impact factor: 15.992

4.  Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L.

Authors:  Abir T El-Alfy; Kelly Ivey; Keisha Robinson; Safwat Ahmed; Mohamed Radwan; Desmond Slade; Ikhlas Khan; Mahmoud ElSohly; Samir Ross
Journal:  Pharmacol Biochem Behav       Date:  2010-03-21       Impact factor: 3.533

5.  Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment.

Authors:  Matthew N Hill; Erica J Carrier; Ryan J McLaughlin; Anna C Morrish; Sarah E Meier; Cecilia J Hillard; Boris B Gorzalka
Journal:  J Neurochem       Date:  2008-07-15       Impact factor: 5.372

Review 6.  Adaptations of striatal endocannabinoid system during stress.

Authors:  Silvia Rossi; Valentina De Chiara; Alessandra Musella; Giorgia Mataluni; Lucia Sacchetti; Giorgio Bernardi; Alessandro Usiello; Diego Centonze
Journal:  Mol Neurobiol       Date:  2009-03-07       Impact factor: 5.590

Review 7.  The endocannabinoid system as a target for the treatment of cannabis dependence.

Authors:  Jason R Clapper; Regina A Mangieri; Daniele Piomelli
Journal:  Neuropharmacology       Date:  2008-07-19       Impact factor: 5.250

8.  Impact of circadian rhythmicity and sleep restriction on circulating endocannabinoid (eCB) N-arachidonoylethanolamine (anandamide).

Authors:  Erin C Hanlon
Journal:  Psychoneuroendocrinology       Date:  2019-10-04       Impact factor: 4.905

9.  Functional Redundancy Between Canonical Endocannabinoid Signaling Systems in the Modulation of Anxiety.

Authors:  Gaurav Bedse; Nolan D Hartley; Emily Neale; Andrew D Gaulden; Toni A Patrick; Philip J Kingsley; Md Jashim Uddin; Niels Plath; Lawrence J Marnett; Sachin Patel
Journal:  Biol Psychiatry       Date:  2017-03-15       Impact factor: 13.382

10.  Sleep Restriction Enhances the Daily Rhythm of Circulating Levels of Endocannabinoid 2-Arachidonoylglycerol.

Authors:  Erin C Hanlon; Esra Tasali; Rachel Leproult; Kara L Stuhr; Elizabeth Doncheck; Harriet de Wit; Cecilia J Hillard; Eve Van Cauter
Journal:  Sleep       Date:  2016-03-01       Impact factor: 5.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.